SIBO and Dysautonomia: Why They Overlap and How to Treat Both

Small intestinal bacterial overgrowth (SIBO) — a condition in which bacteria from the colon migrate into and proliferate in the small intestine — is far more common in patients with dysautonomia than in the general population. The connection is not coincidental: the same autonomic dysfunction that causes POTS also impairs the migrating motor complex (MMC), the intestinal "housekeeper" that sweeps bacteria out of the small bowel between meals.

What Is SIBO?

The small intestine normally contains relatively few bacteria (fewer than 10³ colony-forming units per milliliter) compared to the colon (10¹¹ CFU/mL). SIBO occurs when bacteria — either colonic species that have migrated upward or an overgrowth of normally present species — colonize the small intestine in abnormal numbers.

SIBO produces symptoms through two mechanisms: fermentation of carbohydrates produces gas (hydrogen, methane, or hydrogen sulfide), causing bloating, distension, and altered motility; and bacterial overgrowth can damage the intestinal brush border, impairing nutrient absorption and contributing to leaky gut.

There are three main types of SIBO based on the predominant gas produced: hydrogen-dominant SIBO (associated with diarrhea), methane-dominant SIBO (associated with constipation, also called intestinal methanogen overgrowth or IMO), and hydrogen sulfide SIBO (associated with "rotten egg" gas and diarrhea).

The Dysautonomia-SIBO Connection

The migrating motor complex is a series of electrical waves that sweep through the small intestine during fasting, propelling bacteria and undigested material toward the colon. The MMC is regulated by the autonomic nervous system — specifically, it requires adequate vagal tone and coordinated enteric nervous system activity to function properly.

In dysautonomia, reduced vagal tone and sympathetic overdrive impair MMC function. Bacteria that would normally be swept out of the small intestine are allowed to proliferate. A 2021 study found that patients with POTS had significantly higher rates of SIBO on lactulose breath testing compared to healthy controls, and that SIBO severity correlated with the degree of autonomic dysfunction.

Gastroparesis — delayed gastric emptying, which is common in POTS — further contributes to SIBO by creating a stagnant pool of partially digested food in the upper GI tract that bacteria can colonize.

Diagnosing SIBO

The most widely used test for SIBO is the lactulose or glucose breath test, which measures hydrogen and methane gas produced by bacterial fermentation. A rise in hydrogen of ≥20 ppm above baseline within 90 minutes (lactulose) or 60 minutes (glucose) is considered positive for hydrogen SIBO. Methane levels ≥10 ppm at any point suggest IMO.

Breath testing has limitations — false positives from rapid transit and false negatives from hydrogen sulfide SIBO — but it remains the most accessible non-invasive option. Small bowel aspirate culture (the gold standard) requires endoscopy and is rarely performed outside research settings.

Treatment: Antibiotics and Beyond

Rifaximin is the first-line antibiotic for hydrogen-dominant SIBO. It is minimally absorbed, acts locally in the gut, and has a favorable side effect profile. The standard course is 550 mg three times daily for 14 days. For methane-dominant SIBO/IMO, rifaximin is combined with neomycin or metronidazole, since methanogens are not susceptible to rifaximin alone.

Elemental diet — a liquid diet of pre-digested nutrients that starves bacteria — achieves SIBO clearance rates comparable to antibiotics in some studies and is an option for patients who cannot tolerate antibiotics or who have had multiple treatment failures.

Herbal antimicrobials (berberine, oregano oil, allicin, neem) have modest evidence for SIBO treatment and are preferred by some patients, though they require longer courses (4–6 weeks) and have less robust data than rifaximin.

Preventing Recurrence: The Critical Step

SIBO recurrence rates are high — up to 40–50% within 9 months — if the underlying cause is not addressed. In dysautonomia patients, this means:

Prokinetics to restore MMC function. Low-dose naltrexone (LDN), low-dose erythromycin, prucalopride, and ginger extract all have evidence for improving MMC function and reducing SIBO recurrence. Iberogast (a herbal prokinetic blend) is widely used in Europe and has reasonable evidence for post-SIBO maintenance.

Treating the autonomic dysfunction. Improving orthostatic tolerance reduces sympathetic overdrive and may partially restore vagal tone and MMC activity. This is the most important long-term strategy.

Spacing meals. The MMC only activates during fasting. Frequent snacking prevents MMC activation. Spacing meals 4–5 hours apart (without snacking between) allows the MMC to function and reduces bacterial accumulation.

Low-FODMAP diet during treatment. Reducing fermentable carbohydrates during antibiotic treatment reduces bacterial fuel and may improve symptom resolution, though it should not be maintained long-term as it can worsen dysbiosis.

Key Takeaways

SIBO is a common and underdiagnosed comorbidity in dysautonomia. The connection is mechanistic — autonomic dysfunction impairs the MMC, allowing bacteria to accumulate in the small intestine. Treatment requires both clearing the overgrowth (antibiotics or elemental diet) and addressing the underlying autonomic dysfunction and motility impairment to prevent recurrence.